The current NCCN screening guidelines recommend brain imaging for NSCLC, SCLC, and metastatic or advanced-stage melanoma, but not for any breast cancer subtype (Table 3).8–11 While there are ongoing clinical studies investigating the role of BM screening in HR+, HER2+, TN, and inflammatory breast cancers, to date data are conflicting and require further investigation.44,45 Due to a relative paucity of data, further clinical trials incorporating molecular data into screening guidelines for BM are necessary to rigorously evaluate the benefits of molecular-based BM screening recommendations. This evidence concerns the gene ERBB2 and breast cancer.